BIOVIT Stock Overview
Operates as a medical technology company in Sweden and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Bio Vitos Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.67 |
| 52 Week High | SEK 6.95 |
| 52 Week Low | SEK 0.67 |
| Beta | 1.75 |
| 11 Month Change | -47.66% |
| 3 Month Change | -69.55% |
| 1 Year Change | -72.65% |
| 33 Year Change | -96.79% |
| 5 Year Change | -97.69% |
| Change since IPO | -98.89% |
Recent News & Updates
Shareholder Returns
| BIOVIT | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | -33.7% | -5.8% | -2.4% |
| 1Y | -72.7% | -7.8% | 10.9% |
Return vs Industry: BIOVIT underperformed the Swedish Medical Equipment industry which returned 5% over the past year.
Return vs Market: BIOVIT underperformed the Swedish Market which returned 21.8% over the past year.
Price Volatility
| BIOVIT volatility | |
|---|---|
| BIOVIT Average Weekly Movement | 19.3% |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: BIOVIT's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: BIOVIT's weekly volatility has decreased from 25% to 19% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 1 | Jesper Birgemo | biovitospharma.com |
Bio Vitos Pharma AB (publ) operates as a medical technology company in Sweden and internationally. The company develops and commercializes Helge, which detects hemolysis in vacuum tubes and blood gas samples. It serves emergency departments in the European Union and the United States.
Bio Vitos Pharma AB (publ) Fundamentals Summary
| BIOVIT fundamental statistics | |
|---|---|
| Market cap | SEK 26.40m |
| Earnings (TTM) | -SEK 14.84m |
| Revenue (TTM) | SEK 1.12m |
23.6x
P/S Ratio-1.8x
P/E RatioIs BIOVIT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOVIT income statement (TTM) | |
|---|---|
| Revenue | SEK 1.12m |
| Cost of Revenue | SEK 838.53k |
| Gross Profit | SEK 281.95k |
| Other Expenses | SEK 15.12m |
| Earnings | -SEK 14.84m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.38 |
| Gross Margin | 25.16% |
| Net Profit Margin | -1,324.21% |
| Debt/Equity Ratio | 0% |
How did BIOVIT perform over the long term?
See historical performance and comparison